Compare · NVO vs ZVSA
NVO vs ZVSA
Side-by-side comparison of Novo Nordisk A/S (NVO) and ZyVersa Therapeutics Inc. (ZVSA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ZVSA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $215.95B.
- Over the past year, NVO is down 29.3% and ZVSA is up 0.0% - ZVSA leads by 29.3 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 2 for ZVSA).
- NVO has more recent analyst coverage (25 ratings vs 0 for ZVSA).
- Company
- Novo Nordisk A/S
- ZyVersa Therapeutics Inc.
- Price
- $48.78+1.22%
- $0.30-45.13%
- Market cap
- $215.95B
- -
- 1M return
- +2.89%
- +0.00%
- 1Y return
- -29.29%
- +0.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 4
- 2
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest ZVSA
- ZyVersa Therapeutics Inc. filed SEC Form 8-K: Other Events
- ZyVersa Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events
- ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
- SEC Form 10-Q filed by ZyVersa Therapeutics Inc.
- ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
- SEC Form 10-K filed by ZyVersa Therapeutics Inc.
- ZyVersa Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 8-K filed by ZyVersa Therapeutics Inc.
- ZyVersa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results